Enzyme Replacement Therapy (ERT)

Drug Overview

In the highly specialized field of Nephrology, managing metabolic imbalances is critical to preventing chronic organ damage. Reloxaliase represents a breakthrough in this arena, classified within the Enzyme Replacement Therapy (ERT) drug class. It is specifically engineered to address Hyperoxaluria, a condition characterized by excessive levels of oxalate in the urine, which serves as the primary driver for recurrent kidney stones and systemic oxalosis.

Unlike systemic medications that alter metabolic pathways within the human body, Reloxaliase is a non-absorbed, crystalline Biologic that targets the problem at the point of entry. By addressing the oxalate burden before it reaches the bloodstream, this therapy provides a vital layer of protection for the renal system.

• Generic Name: Reloxaliase
• US Brand Names: Investigational (No commercial brand name assigned as of early 2026).
• Route of Administration: Oral (Capsules).
• FDA Approval Status: Currently in late-stage clinical development (Phase 3). It has been granted Orphan Drug and Fast Track designations by the FDA for the treatment of Enteric Hyperoxaluria.
  +1

What Is It and How Does It Work? (Mechanism of Action)

Reloxaliase is a recombinant oxalate decarboxylase enzyme, a sophisticated Targeted Therapy derived from the fungus Collybia velutipes. Its mechanism is purely intraluminal, meaning it operates entirely within the gastrointestinal tract without being absorbed into the patient’s systemic circulation.

At the molecular level, the mechanism involves the following biochemical pathways:

1. Enzymatic Degradation: Reloxaliase acts as a catalyst for the decarboxylation of oxalate. It specifically targets the carbon-carbon bond of the oxalate molecule (C_{2}O_{4}^{2-}).
2. Molecular Conversion: The enzyme facilitates the breakdown of oxalate into carbon dioxide (CO_{2}) and formate (CHO_{2}^{-}). These two byproducts are naturally occurring, non-toxic, and are either exhaled or excreted through standard metabolic processes.
3. Intraluminal Sequestration: By maintaining high concentrations of the active enzyme in the stomach and small intestine, Reloxaliase degrades both dietary oxalate and endogenous oxalate that is secreted back into the gut.
4. Prevention of Absorption: Because the oxalate is destroyed in the gut, it cannot be transported across the intestinal epithelium into the blood. This prevents the subsequent formation of insoluble calcium-oxalate crystals in the renal tubules, thereby halting the progression of nephrocalcinosis and stone formation.

FDA-Approved Clinical Indications

Primary Indication

• Prevention of Oxalate Absorption in Hyperoxaluria: Specifically indicated to reduce the oxalate burden in patients with Enteric Hyperoxaluria (often associated with Crohn’s disease, bariatric surgery, or short bowel syndrome) to prevent recurrent kidney stones and protect the kidneys from crystal-induced injury.

Other Approved Uses

• Primary Hyperoxaluria (Investigational): Being studied as a supportive therapy to reduce the total body burden of oxalate in patients with genetic mutations (PH1, PH2, PH3) that cause internal overproduction of oxalate.

Dosage and Administration Protocols

Dosing for Reloxaliase is timed with nutritional intake to ensure the enzyme is present when oxalate concentration is at its peak in the gut.

Special Populations

• Renal Insufficiency: Because Reloxaliase is not absorbed into the blood and does not rely on renal clearance, no dose adjustment is required for patients with Chronic Kidney Disease (CKD) or even End-Stage Renal Disease (ESRD).
• Hepatic Insufficiency: No adjustments are necessary as the drug does not undergo hepatic metabolism.

Clinical Efficacy and Research Results

Clinical data from the 2020-2026 period, specifically from the URIROX-1 and URIROX-2 clinical programs, have provided precise numerical evidence of Reloxaliase’s efficacy.

• Urinary Oxalate Reduction: Phase 3 data showed that patients treated with Reloxaliase achieved a mean reduction in 24-hour urinary oxalate (UOx) of 22.6% to 25% compared to placebo.
• Responder Rates: Approximately 50% of patients achieved a clinically significant reduction (\ge20%) in urinary oxalate, which is the threshold associated with a decreased risk of kidney stone formation.
• Stone Event Reduction: Long-term follow-up data (2025) suggests a trend toward a 30% reduction in the frequency of symptomatic kidney stone events over a 2-year period in compliant patients.

Safety Profile and Side Effects

Reloxaliase is generally well-tolerated due to its non-absorbed, local mechanism. There is currently no Black Box Warning for this medication.

Common Side Effects (>10%)

• Gastrointestinal: Mild to moderate abdominal pain, flatulence, and diarrhea.
• Metabolic: Changes in appetite.

Serious Adverse Events

• Hypersensitivity: Although rare, as a Biologic, there is a theoretical risk of an allergic reaction to the fungal enzyme.
• Vitamin/Mineral Interference: Prolonged use may occasionally impact the absorption of certain minerals, though this has not reached clinical significance in current trials.

Management Strategies: GI symptoms are often transient and can be managed by adjusting the timing of administration or the composition of meals.

Research Areas

In the realm of modern nephrology, the focus has shifted toward the combination of Enzyme Replacement Therapy and Research Areas involving the gut microbiome. While there is no current combination with stem cell therapy, researchers are investigating the use of Reloxaliase alongside “probiotic” interventions (such as Oxalobacter formigenes colonization). The goal is to create a multi-layered intestinal shield—using both a synthetic enzyme and live bacterial repair—to maximize the degradation of oxalate. Furthermore, current trials are evaluating the drug’s ability to “prime” the kidneys for potential Tissue Repair by removing the inflammatory crystal burden that prevents native renal regeneration.

Patient Management and Practical Recommendations

Pre-treatment Tests

• 24-Hour Urine Collection: Mandatory baseline measurement of urinary oxalate, calcium, and creatinine.
• Renal Imaging: Ultrasound or CT scan to document the baseline number and size of existing stones.
• Blood Chemistry: Baseline serum oxalate and electrolyte panel.

Precautions During Treatment

• Meal Compliance: The drug is only effective if taken with food. Skipping doses during meals significantly reduces therapeutic benefit.
• Dietary Hydration: Maintain high fluid intake (target >2.5L/day) to support renal flushing.

Do’s and Don’ts

• DO take your capsules within the first few bites of your meal.
• DO keep your 24-hour urine collection appointments, as these are the only way to track if the medication is working.
• DON’T crush or chew the capsules; they must remain intact to protect the enzyme from premature degradation by stomach acid.
• DON’T significantly alter your dietary oxalate intake (e.g., suddenly eating massive amounts of spinach) just because you are on the medication.

Legal Disclaimer

This guide is for informational purposes only and does not replace professional medical advice, diagnosis, or treatment. Reloxaliase is an investigational drug; its safety and efficacy are still being finalized in clinical settings. Always consult your nephrologist or qualified healthcare provider regarding your specific medical condition or treatment plan.